Psychiatry

News

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.

News

Helus' psychedelic derived from ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression.

R&D

Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.

News

Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.

News

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

News

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.